This report evaluates the clinical utility of pharmacogenomic testing to inform the selection or dose of medications for individuals diagnosed with depression, bipolar disorder, schizophrenia spectrum or other psychotic disorder, or anxiety disorder to improve clinical outcomes.

If you have a Hayes login, click here to view the full report on the Knowledge Center.